Please wait while the formulary information is being retrieved.
GAMUNEX-C (IMMUNE GLOBULIN,GAMMA CAPRYLATE (IGG))
- Idiopathic thrombocytopenic purpura
- Primary immune deficiency disorder
- Agammaglobulinemia
- Chronic inflammatory demyelinating polyneuropathy
- Common variable agammaglobulinemia
- Severe combined immunodeficiency disease
- Wiskott-aldrich syndrome
- X-linked agammaglobulinemia
1 gram/10 mL (10 %) injection solution
- Infuse 1 gram/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
10 gram/100 mL (10 %) injection solution
- Infuse 1 gram/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
2.5 gram/25 mL (10 %) injection solution
- Infuse 1 gram/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
20 gram/200 mL (10 %) injection solution
- Infuse 1 gram/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
40 gram/400 mL (10 %) injection solution
- Infuse 1 gram/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
5 gram/50 mL (10 %) injection solution
- Infuse 1 gram/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
1 gram/10 mL (10 %) injection solution
- Infuse 1 gram/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
10 gram/100 mL (10 %) injection solution
- Infuse 1 gram/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
2.5 gram/25 mL (10 %) injection solution
- Infuse 1 gram/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
20 gram/200 mL (10 %) injection solution
- Infuse 1 gram/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
5 gram/50 mL (10 %) injection solution
- Infuse 1 gram/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
Agammaglobulinemia
- Infuse 300 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
Chronic inflammatory demyelinating polyneuropathy
- Infuse 1 gram/kg by intravenous route at a rate of 2 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 0.5 gram/kg by intravenous route at a rate of 2 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min for 2 days
- Infuse 0.5 gram/kg by intravenous route every 3 weeks for 2 consecutive days at a rate of 2 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min for 2 consecutive days each month
Common variable agammaglobulinemia
- Infuse 300 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
Idiopathic thrombocytopenic purpura
- Infuse 1 gram/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 1 gram/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min for 2 days
- Infuse 0.4 gram/kg by intravenous route at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min for 5 days
Primary immune deficiency disorder
- Infuse 300 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
Severe combined immunodeficiency disease
- Infuse 300 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
Wiskott-aldrich syndrome
- Infuse 300 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
X-linked agammaglobulinemia
- Infuse 300 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 300 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route at a rate of 1 mg/kg/min for 30Minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 3 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- Infuse 600 mg/kg by intravenous route every 4 weeks at a rate of 1 mg/kg/min for 30 minutes, then may increase to 8 mg/kg/min
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- Proquad (pf)
- varicella virus vacc live (PF)
- Varivax (pf)
- yellow fever vaccine live (PF)
- Yf-vax (pf)
Contraindicated
- None
Severe
Moderate
- Activella
- Alora
- Altavera (28)
- Alyacen 1/35 (28)
- Alyacen 7/7/7 (28)
- Amethia
- Amethia Lo
- Amethyst
- Angeliq
- Apri
- Aranelle (28)
- Aubra
- Aviane
- Azurette (28)
- Balziva (28)
- Beyaz
- Brevicon (28)
- Briellyn
- Camrese
- Camrese Lo
- Caziant (28)
- Cenestin
- Chateal
- Climara
- Climara Pro
- Combipatch
- conj estrogens-bazedoxifene
- conjugated estrogens
- Covaryx
- Covaryx H.s.
- Cryselle (28)
- Cyclafem 1/35 (28)
- Cyclafem 7/7/7 (28)
- Cyclessa (28)
- Dasetta 1/35 (28)
- Dasetta 7/7/7 (28)
- Daysee
- Delestrogen
- Depo-estradiol
- desog-e.estradiol/e.estradiol
- Desogen
- desogestrel-ethinyl estradiol
- Divigel
- drospirenone-e.estradiol-lm.FA
- drospirenone-estradiol
- drospirenone-ethinyl estradiol
- Duavee
- Eemt
- Eemt Hs
- Elestrin
- Elinest
- Emoquette
- Enjuvia
- Enpresse
- Enskyce
- Estarylla
- esterified estrogens
- Estrace
- estradiol
- estradiol acetate
- estradiol cypionate
- Estradiol Transdermal Patch
- estradiol valerate
- estradiol valerate-dienogest
- estradiol-levonorgestrel
- estradiol-norethindrone acet
- estradiol-norgestimate
- Estrasorb
- Estring
- Estrogel
- estrogens-methyltestosterone
- estropipate
- Estrostep Fe-28
- ethynodiol diac-eth estradiol
- etonogestrel-ethinyl estradiol
- Evamist
- Falmina (28)
- Femcon Fe
- Femhrt Low Dose
- Femring
- Generess Fe
- Gianvi (28)
- Gildagia
- Gildess
- Gildess Fe
- Introvale
- Jinteli
- Jolessa
- Junel 1.5/30 (21)
- Junel 1/20 (21)
- Junel Fe 1.5/30 (28)
- Junel Fe 1/20 (28)
- Kariva (28)
- Kelnor 1/35 (28)
- Kurvelo
- L norgest&E estradiol-E estrad
- Larin 1/20 (21)
- Larin Fe
- Leena 28
- Lessina
- Levonest (28)
- levonorg-eth estrad triphasic
- levonorgestrel-ethinyl estrad
- Levora 0.15/30 (28)
- Levora-28
- Lo Loestrin Fe
- Loestrin 1.5/30 (21)
- Loestrin 1/20 (21)
- Loestrin Fe 1.5/30 (28)
- Loestrin Fe 1/20 (28)
- Lomedia 24 Fe
- Loryna (28)
- Loseasonique
- Low-ogestrel (28)
- Lutera (28)
- Marlissa
- Menest
- Menostar
- Microgestin 1.5/30 (21)
- Microgestin 1/20 (21)
- Microgestin Fe 1.5/30 (28)
- Microgestin Fe 1/20 (28)
- Mimvey
- Minastrin 24 Fe
- Minivelle
- Mircette (28)
- Modicon (28)
- Mono-linyah
- Mononessa (28)
- Myzilra
- Natazia
- Necon 0.5/35 (28)
- Necon 1/35 (28)
- Necon 1/50 (28)
- Necon 10/11 (28)
- Necon 7/7/7 (28)
- norelgestrom-ethinyl estradiol
- noreth-ethinyl estradiol-iron
- norethin-e.estradiol triphasic
- norethin-eth estrad biphasic
- norethindrone ac-eth estradiol
- norethindrone-e.estradiol-iron
- norethindrone-ethin estradiol
- norethindrone-mestranol
- norgestimate-ethinyl estradiol
- norgestrel-ethinyl estradiol
- Norinyl 1+35 (28)
- Norinyl 1+50 (28)
- Nortrel 0.5/35 (28)
- Nortrel 1/35 (21)
- Nortrel 1/35 (28)
- Nortrel 7/7/7 (28)
- Nuvaring
- Ocella
- Ogen 2.5
- Ogestrel (28)
- Orsythia
- Ortho Evra
- Ortho Tri-cyclen (28)
- Ortho Tri-cyclen Lo (28)
- Ortho-cept (28)
- Ortho-cyclen (28)
- Ortho-novum 1/35 (28)
- Ortho-novum 7/7/7 (28)
- Ovcon-35 (28)
- Philith
- Pimtrea (28)
- Pirmella
- Portia
- Prefest
- Premarin
- Previfem
- Quartette
- Quasense
- Reclipsen (28)
- Safyral
- Seasonique
- Sprintec (28)
- Sronyx
- Syeda
- synthetic conj estrogens A
- synthetic conj estrogens B
- Tilia Fe
- Tri-estarylla
- Tri-legest Fe
- Tri-linyah
- Tri-norinyl (28)
- Tri-previfem (28)
- Tri-sprintec (28)
- Trinessa (28)
- Trivora (28)
- Vagifem
- Velivet Triphasic Regimen (28)
- Vestura (28)
- Viorele (28)
- Vivelle-dot
- Vyfemla (28)
- Wera (28)
- Wymzya Fe
- Yasmin (28)
- Yaz 28
- Zarah
- Zenchent (28)
- Zenchent Fe
- Zeosa
- Zovia 1/35E (28)
- Zovia 1/50E (28)
- None
Contraindicated
- Hemolytic anemia
- Non-infective meningitis
- Predisposition to thrombosis
- Thromboembolic disorder
Severe
Moderate
- Atherosclerotic cardiovascular disease
- Bed-ridden
- Chronic heart failure
- Diabetes mellitus
- Hypertension
- Hypovolemia
- Increased cardiovascular event risk
- Kidney disease with reduction in GFR
- Monoclonal gammopathy
- Sepsis
- Transfusion related acute lung injury
GAMUNEX-C (IMMUNE GLOBULIN,GAMMA CAPRYLATE (IGG))
- Idiopathic thrombocytopenic purpura
- Primary immune deficiency disorder
- Agammaglobulinemia
- Chronic inflammatory demyelinating polyneuropathy
- Common variable agammaglobulinemia
- Severe combined immunodeficiency disease
- Wiskott-aldrich syndrome
- X-linked agammaglobulinemia
- Tachycardia
- Arthralgias
- Chills
- Cough
- Diarrhea
- Dizziness
- Earache
- Edema
- Fatigue
- Fever
- Headache disorder
- Injection site sequelae
- Nausea
- Pharyngitis
- Skin rash
- Vomiting
More Frequent
Severe
Less Severe
- Dyspnea
- Wheezing
- Cramps
- Malaise
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Anaphylaxis
- Bronchospastic pulmonary disease
- Bullous dermatitis
- Cerebrovascular accident
- Chest pain
- Cyanosis
- Disseminated intravascular coagulation
- Erythema multiforme
- Hemolysis
- Hemolytic anemia
- Hyperproteinemia
- Hypertension
- Hypotension
- Kidney disease with reduction in GFR
- Leukopenia
- Migraine
- Non-infective meningitis
- Pancytopenia
- Pseudohyponatremia
- Pulmonary edema
- Pulmonary thromboembolism
- Renal failure
- Seizure disorder
- Stevens-johnson syndrome
- Thromboembolic disorder
- Thrombotic disorder
Less Severe
- Back pain
- Flushing
- General weakness
- Hematuria
- Myalgias
- Photophobia
- Pruritus of skin
- Tremor
- Urine discoloration
- Urticaria
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Immune Globulin,gamma (igg)
- Severity Level:
2
- Additional Notes: Insuff human/animal data avail, consider maternal tx benefit vs poss fetal risk
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Immune Globulin,gamma (igg)
Insufficient data available.
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available. |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Immune Globulin Parenteral (human)
General-Administer at the minimum infusion rate and do not exceed recommended dose. Renal-Increased risk of acute kidney injury in patients with decreased renal function. Cardiovascular-May be at increased risk of thrombosis. Assure adequate hydration and not volume depleted. Risk increases with immobility, hyperviscosity and underlying cardiovascular risks.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | Y | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- This medication may cause serious (rarely fatal) kidney problems. This risk is higher if you have kidney problems, diabetes, a serious blood infection (sepsis), a certain blood problem (paraproteinemia), or a severe loss of body fluids (dehydration), as well as if you are older than 65 years or are using other drugs that may harm the kidneys (such as gentamicin). This medication may also rarely cause serious blood clots (such as pulmonary embolism, stroke, heart attack, deep vein thrombosis).<br /><br />You may be at increased risk for blood clots if you are an older adult, are severely dehydrated, have a catheter in a vein close to your heart for administering medications, or have a history of blood clots, heart/blood vessel disease, heart failure, stroke, or if you are immobile (such as very long plane flights or bedridden). If you use estrogen-containing products, these may also increase your risk. Before using this medication, discuss the risks and benefits and if you have any of these conditions, report them to your doctor or pharmacist.<br /><br />The risk of kidney problems and blood clots may be decreased by infusing this medication more slowly or by using a less concentrated form of this medication if available. Being adequately hydrated before receiving this medication may also help reduce these risks. Get medical help right away if any of these side effects occur: sudden weight gain, swelling of the hands/ankles/feet, a change in the amount of urine, shortness of breath/rapid breathing, chest/jaw/left arm pain, unusual sweating, sudden dizziness/fainting, pain/swelling/warmth in the arm/leg, sudden/severe headache, slurred speech, weakness on one side of the body, sudden vision changes, or confusion.
| Agammaglobulinemia | |
| D80.0 | Hereditary hypogammaglobulinemia |
| D80.1 | Nonfamilial hypogammaglobulinemia |
| Chronic inflammatory demyelinating polyneuropathy | |
| G61.81 | Chronic inflammatory demyelinating polyneuritis |
| Common variable agammaglobulinemia | |
| D80.1 | Nonfamilial hypogammaglobulinemia |
| D83 | Common variable immunodeficiency |
| D83.0 | Common variable immunodeficiency with predominant abnormalities of b-cell numbers and function |
| D83.1 | Common variable immunodeficiency with predominant immunoregulatory t-cell disorders |
| D83.2 | Common variable immunodeficiency with autoantibodies to b- or t-cells |
| D83.8 | Other common variable immunodeficiencies |
| D83.9 | Common variable immunodeficiency, unspecified |
| Idiopathic thrombocytopenic purpura | |
| D69.3 | Immune thrombocytopenic purpura |
| Primary immune deficiency disorder | |
| D84.9 | Immunodeficiency, unspecified |
| Severe combined immunodeficiency disease | |
| D81.0 | Severe combined immunodeficiency [SCId] with reticular dysgenesis |
| D81.1 | Severe combined immunodeficiency [SCId] with low t- and b-cell numbers |
| D81.2 | Severe combined immunodeficiency [SCId] with low or normal b-cell numbers |
| D81.31 | Severe combined immunodeficiency due to adenosine deaminase deficiency |
| Wiskott-aldrich syndrome | |
| D82.0 | Wiskott-aldrich syndrome |
| X-linked agammaglobulinemia | |
| D80.0 | Hereditary hypogammaglobulinemia |
| 0-9 | A-Z |
|---|---|
| D69.3 | Immune thrombocytopenic purpura |
| D80.0 | Hereditary hypogammaglobulinemia |
| D80.0 | Hereditary hypogammaglobulinemia |
| D80.1 | Nonfamilial hypogammaglobulinemia |
| D80.1 | Nonfamilial hypogammaglobulinemia |
| D81.0 | Severe combined immunodeficiency [SCId] with reticular dysgenesis |
| D81.1 | Severe combined immunodeficiency [SCId] with low t- and b-cell numbers |
| D81.2 | Severe combined immunodeficiency [SCId] with low or normal b-cell numbers |
| D81.31 | Severe combined immunodeficiency due to adenosine deaminase deficiency |
| D82.0 | Wiskott-aldrich syndrome |
| D83 | Common variable immunodeficiency |
| D83.0 | Common variable immunodeficiency with predominant abnormalities of b-cell numbers and function |
| D83.1 | Common variable immunodeficiency with predominant immunoregulatory t-cell disorders |
| D83.2 | Common variable immunodeficiency with autoantibodies to b- or t-cells |
| D83.8 | Other common variable immunodeficiencies |
| D83.9 | Common variable immunodeficiency, unspecified |
| D84.9 | Immunodeficiency, unspecified |
| G61.81 | Chronic inflammatory demyelinating polyneuritis |
Formulary Reference Tool